Sunitinib is a type of targeted therapy known as a tyrosine kinase inhibitor (TKI). It is primarily used to treat certain kinds of cancer by blocking proteins called tyrosine kinases that are involved in the growth and spread of cancer cells. Developed by Pfizer, sunitinib is marketed under the brand name Sutent.
